Therefore, therapeutic strategies aimed at preserving IL-17/IL-22 producing cells or their function during HIV infection may prevent the loss of epithelial integrity and prevent the microbial translocation which leads to immune activation and higher levels of SIV/HIV replication [7,34,41,47,50]. This evidence concerns the gene IL17A and HIV infectious disease.